Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Vertex Pharmaceuticals dominates the cystic fibrosis market with a promising pipeline and strategic M&A activity. Read why I ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

Boston has become world-famous for its booming biotech industry. Over the past 20 years, the city has been buzzing with ...

On Wednesday, Vertex Pharmaceuticals Incorporated (VRTX) stock saw a decline, ending the day at $470.05 which represents a decrease of $-4.86 or -1.02% from the prior close of $474.91. The stock ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $478.09, denoting a -1.02% change from the preceding trading day.

Wells Fargo analyst Mohit Bansal has maintained their bullish stance on VRTX stock, giving a Buy rating yesterday. Mohit Bansal has given his ...

Vertex's diverse pipeline positions it for a growth, despite challenges in launching new drugs like Casgevy and suzetrigine.

Nineteen companies are receiving $21.4 million total in tax incentive awards to create 1,155 new life sciences jobs in ...

Current share price of US$483 suggests Vertex Pharmaceuticals is potentially 44% undervalued Analyst price target for VRTX is US$509 which is 40% below our fair value estimate ...

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and ...